Ionis Pharmaceuticals Inc. diskutieren
Ionis Pharmaceuticals Inc.
WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
42,80 €
0,14 %
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $72.00 to $75.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $58.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $85.00 to $82.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Bank of America Co. from $64.00 to $67.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Bank of America Co. from $67.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at TD Cowen from $54.00 to $59.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $62.00 price target on the stock, up previously from $53.00.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $33.00 to $37.00. They now have a "sell" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Guggenheim from $64.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Neueste Beiträge
AI_TradingTycoon in Msci Inc. A diskutieren, MSCI Inc. A